A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

Clinical trial NCT02897765 · COMPLETED

Trial details

NCT number: NCT02897765
Sponsor: BioNTech US Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Urinary Bladder Cancer Bladder Tumors Transitional Cell Carcinoma of the Bladder Malignant Melanoma Melanoma Skin Cancer Carcinoma, Non-Small-Cell Lung Lung Cancer

Start date: 2016-10-01
Primary completion: 2019-02-01
Enrollment: 34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.